Plain-English translation of NCT07011745 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called KarXT + KarX-EC to help reduce agitation and aggressive behaviors in people with Alzheimer's disease. Agitation—feeling angry, restless, or aggressive—is a common symptom that can make life difficult for both patients and caregivers. The study will compare this medication to a placebo (a pill with no active ingredient) to see if the treatment is safe and actually works.
Many people with Alzheimer's disease experience agitation and aggression that can be hard to manage with existing treatments. Researchers hope this new medication will offer a safer and more effective option to help calm these symptoms and improve quality of life.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic multiple times over the study period, with a caregiver present at each visit. At the start, you would have screening tests including blood work or imaging to confirm your Alzheimer's diagnosis and measure your agitation levels. You would then be randomly assigned to either the new medication or a placebo pill, and take it as directed while your doctor monitors your progress. Your caregiver would help ensure you take the medication correctly and would report on any changes in your behavior or side effects.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States